CRSP
Crispr Therapeutics AG
55.70$
-0.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -193.1% | – | – | – | -520.6% | – | -192.0% | – | – | – | |
| – | +234.2% | +628.3% | +226.9% | +16.4% | +34.3% | +94.4% | +95.5% | +34.6% | -17.9% | -2.9% | +1.1% | |
| – | +430.1% | +194.4% | +74.0% | +85.4% | +25.9% | +49.8% | +55.1% | -4.3% | -17.3% | +6.8% | -16.3% | |
| – | – | -1,113.9% | – | +68.8% | +42.2% | +37.1% | +50.9% | +7.8% | – | – | – | |
| – | +5,204.3% | -97.8% | -1,525.7% | – | -559.1% | – | -19.7% | -26.1% | -1,075.5% | – | -54.0% | |
| – | +0.0% | +161.4% | +159.1% | -64.5% | +141.0% | +174.7% | +345.1% | -54.5% | -74.5% | -79.9% | -51.9% | |
| – | +0.0% | – | -126.1% | -66.6% | – | -40,943.0% | +91.3% | -75.0% | – | -174.9% | -88.7% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +267,463.6% | +95.4% | -97.7% | -102.2% | – | +135.8% | -75.3% | -84.6% | – | – | – | |
| – | +0.0% | -8.4% | – | – | – | – | – | – | – | – | – | |
| – | +1,788.2% | +89.4% | -98.6% | +12,014.0% | +36.4% | +135.8% | -75.3% | -84.6% | +62.4% | +429.8% | +28.3% | |
| – | +26,443.8% | +2.9% | -147.5% | – | +125.4% | -51.6% | -203.7% | – | – | -151.4% | – | |
| – | – | -200.1% | – | – | – | -613.5% | – | -216.5% | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.